UltraSoc needed an immediate sales presence on the ground to capture the growing opportunity in China for its on-chip debug tools. 

Intralink targeted major players who were either developing highly complex chips or working on RISC-V core-based designs. Targets included HiSilicon, Spreadtrum, Phytium, MediaTek, Realtek, Sanechips, and Horizon Robotics - companies that UltraSoc had yet to engage. 

This direct sales approach resulted in successful licensing deals, including with HiSilicon, and formed the basis for Ultrasoc to establish its own entity in the territory. It has also contributed to UltraSoC's subsequent acquisition by Siemens in 2020.

Ceres, a British company specialising in solid oxide fuel cell (SOFC) technology, already had a Korean partner. But the relationship was a difficult one and progress was slow.

We decided to take a different approach, focusing on potential new partners with a greater appetite and technical capacity to develop fuel cell products. 

We identified an opportunity with Korea’s largest fuel cell player, Doosan, and ultimately enabled Ceres to license its technology to Doosan in a series of deals worth US$ 57 million.

As part of delivering an opportunity assessment for Owen Mumford’s highly innovative Unisafe® safety syringe in Japan, we facilitated an exhibition for the firm at Interphex Tokyo. It was through this that we first attracted interest from Nipro - one of Japan’s top medical device manufacturers.

We played an active role in not only managing the day-to-day interactions and deepening the relationship between Owen Mumford and Nipro, but negotiating the scope of the partnership. This resulted in an exclusive distribution agreement between the two parties in Japan.